Pfizer: marketing deal with Switzerland's Basilea.
(CercleFinance.com) - Pfizer has entered into a partnership with Switzerland's Basilea, the US biopharmaceutical giant said on Friday.
Under the terms of the deal, Pfizer will be granted the exclusive development and marketing rights in China and 16 other Asian countries to antifungal Cresemba (isavuconazole).
The drug was approved by the US FDA in March 2015 for the treatment of invasive aspergillosis and invasive mucormycosis, two serious infections associated with HIV and cancer.
Pfizer's rights will not include Japan.
Copyright (c) 2017 CercleFinance.com. All rights reserved.